Anastrozole vs CJC-1295 with DAC
FDA Approved vs Well Studied
synergistic Mechanism-based · 60% CJC-1295 with DAC helps manage estrogen conversion from Anastrozole. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
Anastrozole CJC-1295 with DAC
Weight 293.37 Da 3,647.28 Da
Half-life ~40-50 hours 6-8 days
Chain — 30 amino acids
Type Nonsteroidal aromatase inhibitor (triazole derivative) GHRH analog with DAC
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dosing Protocols
Anastrozole
0.25-0.5mg EOD or E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Diabetes history
Cancer history
Predisposed sleep apnea
Research Evidence
Anastrozole CJC-1295 with DAC
Status FDA Approved Well Studied
References 5 studies 4 studies
Latest — 2025
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.